CEL-SCI Corporation (CVM)

1.5600 +0.0600 (+4.00%) At close: 04:00PM EDT

CEL-SCI Corporation

8229 Boone Boulevard
Suite 802
Vienna, VA 22182
United States
703 506 9460
https://cel-sci.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Geert R. Kersten Esq.	Chief Executive & Financial Officer, Treasurer and Director	702.79k	N/A	1959
Ms. Patricia B. Prichep	Senior VP of Operations & Corporate Secretary	295.18k	N/A	1951
Dr. Eyal Talor Ph.D.	Chief Scientific Officer	351.88k	N/A	1956
Dr. Daniel H. Zimmerman Ph.D.	Senior Vice President of Research & Cellular Immunology	46.08k	N/A	1941
Mr. John Cipriano	Senior Vice President of Regulatory Affairs	246.97k	N/A	1942

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

Corporate governance

CEL-SCI Corporation’s ISS governance QualityScore as of 1 April 2024 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder rights: 6; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.